Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells
- PMID: 15085191
- PMCID: PMC385395
- DOI: 10.1172/JCI19205
Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells
Abstract
Gene-based delivery can establish a sustained supply of therapeutic proteins within the nervous system. For diseases characterized by extensive CNS and peripheral nervous system (PNS) involvement, widespread distribution of the exogenous gene may be required, a challenge to in vivo gene transfer strategies. Here, using lentiviral vectors (LVs), we efficiently transduced hematopoietic stem cells (HSCs) ex vivo and evaluated the potential of their progeny to target therapeutic genes to the CNS and PNS of transplanted mice and correct a neurodegenerative disorder, metachromatic leukodystrophy (MLD). We proved extensive repopulation of CNS microglia and PNS endoneurial macrophages by transgene-expressing cells. Intriguingly, recruitment of these HSC-derived cells was faster and more robust in MLD mice. By transplanting HSCs transduced with the arylsulfatase A gene, we fully reconstituted enzyme activity in the hematopoietic system of MLD mice and prevented the development of motor conduction impairment, learning and coordination deficits, and neuropathological abnormalities typical of the disease. Remarkably, ex vivo gene therapy had a significantly higher therapeutic impact than WT HSC transplantation, indicating a critical role for enzyme overexpression in the HSC progeny. These results indicate that transplantation of LV-transduced autologous HSCs represents a potentially efficacious therapeutic strategy for MLD and possibly other neurodegenerative disorders.
Figures
Comment in
-
Blood to brain to the rescue.J Clin Invest. 2004 Apr;113(8):1108-10. doi: 10.1172/JCI21476. J Clin Invest. 2004. PMID: 15085187 Free PMC article.
Similar articles
-
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.J Clin Invest. 2006 Nov;116(11):3070-82. doi: 10.1172/JCI28873. J Clin Invest. 2006. PMID: 17080200 Free PMC article.
-
Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy.Hum Gene Ther. 2007 Sep;18(9):821-36. doi: 10.1089/hum.2007.048. Hum Gene Ther. 2007. PMID: 17845130
-
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.Lancet. 2016 Jul 30;388(10043):476-87. doi: 10.1016/S0140-6736(16)30374-9. Epub 2016 Jun 8. Lancet. 2016. PMID: 27289174 Clinical Trial.
-
Developing therapeutic approaches for metachromatic leukodystrophy.Drug Des Devel Ther. 2013 Aug 8;7:729-45. doi: 10.2147/DDDT.S15467. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 23966770 Free PMC article. Review.
-
Atidarsagene autotemcel for metachromatic leukodystrophy.Drugs Today (Barc). 2023 Feb;59(2):63-70. doi: 10.1358/dot.2023.59.2.3461911. Drugs Today (Barc). 2023. PMID: 36811406 Review.
Cited by
-
Therapeutic approaches for lysosomal storage diseases.Ther Adv Endocrinol Metab. 2010 Aug;1(4):177-88. doi: 10.1177/2042018810384429. Ther Adv Endocrinol Metab. 2010. PMID: 23148162 Free PMC article.
-
Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice.Mol Neurobiol. 2022 Jul;59(7):4159-4178. doi: 10.1007/s12035-022-02838-y. Epub 2022 Apr 30. Mol Neurobiol. 2022. PMID: 35501630 Free PMC article.
-
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.Hum Gene Ther. 2005 Jun;16(6):741-51. doi: 10.1089/hum.2005.16.741. Hum Gene Ther. 2005. PMID: 15960605 Free PMC article.
-
Recent advances in lentiviral vector development and applications.Mol Ther. 2010 Mar;18(3):477-90. doi: 10.1038/mt.2009.319. Epub 2010 Jan 19. Mol Ther. 2010. PMID: 20087315 Free PMC article. Review.
-
Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside.Cells. 2021 Nov 23;10(12):3273. doi: 10.3390/cells10123273. Cells. 2021. PMID: 34943781 Free PMC article. Review.
References
-
- Kolodney, E.H., and Fluharty, A.L. 1995. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In The metabolic and molecular bases of inherited disease. 6th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, New York, USA. 2693–7391.
-
- Neufeld EF. Lysosomal disease. Annu. Rev. Biochem. 1991;60:257–280. - PubMed
-
- Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 2001;7:33–40. - PubMed
-
- Glorioso JC, Mata M, Fink DJ. Therapeutic gene transfer to the nervous system using viral vectors. J. Neurovirol. 2003;9:165–172. - PubMed
-
- Consiglio A, et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 2001;7:310–316. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical